Phenylalanine

Phenylalanine

SCHEMBL3047281

N[C@@H](Cc1ccccc1)C(=O)O.O=C(O)C(F)(F)F

nearest known ligand 0.81

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 3/20 0.81
ALPI P09923 1/20 0.81
PKM P14618 1/20 0.81
PTGS1 P23219 1/20 0.81
XIAP P98170 1/20 0.81
GRB2 P62993 1/20 0.68
PTPN1 P18031 2/20 0.62
SLC1A3 P43003 2/20 0.59
SLC1A2 P43004 2/20 0.59
SLC1A1 P43005 2/20 0.59
CPA1 P15085 1/20 0.56
SLC15A1 P46059 1/20 0.54
CYP1A2 P05177 1/20 0.52
LTA4H P09960 1/20 0.51
GRIA2 P42262 1/20 0.51
TPH1 P17752 1/20 0.50
NOS3 P29474 1/20 0.50
NOS1 P29475 1/20 0.50
NOS2 P35228 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phenylalanine SCHEMBL3050654 1.00 SLC7A5 (0.81) SLC7A5ALPIPKMPTGS1XIAP
Dl-Phenylalanine SCHEMBL16649156 1.00 SLC7A5 (0.81) SLC7A5ALPIPKMPTGS1XIAP
D-Phenylalanine SCHEMBL3054019 1.00 SLC7A5 (0.81) SLC7A5ALPIPKMPTGS1XIAP
Dl-Phenylalanine SCHEMBL7450242 1.00 SLC7A5 (0.81) SLC7A5ALPIPKMPTGS1XIAP
SCHEMBL23159186 0.90 SLC7A5 (1.00) SLC7A5ALPIPKMPTGS1XIAP
D-Phenylalanine SCHEMBL837632 0.90 SLC7A5 (1.00) SLC7A5ALPIPKMPTGS1XIAP
Dl-Phenylalanine SCHEMBL16398196 0.90 SLC7A5 (1.00) SLC7A5ALPIPKMPTGS1XIAP
Dl-Phenylalanine SCHEMBL8118 0.90 SLC7A5 (1.00) SLC7A5ALPIPKMPTGS1XIAP
Dl-Phenylalanine SCHEMBL385804 0.90 SLC7A5 (1.00) SLC7A5ALPIPKMPTGS1XIAP
Phenylalanine SCHEMBL16398197 0.90 SLC7A5 (1.00) SLC7A5ALPIPKMPTGS1XIAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118724745-A Asymmetric chiral gel factor for supermolecule assembly and preparation method and application thereof 河南大学 2024-10-01 CN claimed
US-20080070884-A1 Antibiotics; novel class of cell wall biosynthesis inhibitors without cross-resistances to known classes of antibiotics; active analogs of lysobactin with a higher ring stability AICURIS GMBH & CO. KG (DE) 2008-03-20 US claimed
CN-118724745-A Asymmetric chiral gel factor for supermolecule assembly and preparation method and application thereof 河南大学 2024-10-01 CN disclosed
EP-3856258-B1 SULFOMALEIMIDE-BASED LINKERS AND CORRESPONDING CONJUGATES PF MEDICAMENT (FR) 2024-07-31 EP disclosed
US-11661457-B2 IGF-1R antibody-drug-conjugate and its use for the treatment of cancer PIERRE FABRE MEDICAMENT (FR) 2023-05-30 US disclosed
US-20100204119-A1 4-AMINO-5-OXO-7,8-DIHYDROPYRIMIDO[5,4-F][1,4]OXAZEPIN-6(5H)-YL PHENYL DERIVATIVES PFIZER INC 2010-08-12 US disclosed
US-20100197591-A1 4-AMINO-7,8-DIHYDROPYRIDO[4,3-d]PYRIMIDIN-5(6H)-ONE DERIVATIVES PFIZER INC 2010-08-05 US disclosed
US-7718611-B2 Cyclic nonapeptide amides AICURIS GMBH & CO. KG (DE) 2010-05-18 US disclosed
US-20080070884-A1 Antibiotics; novel class of cell wall biosynthesis inhibitors without cross-resistances to known classes of antibiotics; active analogs of lysobactin with a higher ring stability AICURIS GMBH & CO. KG (DE) 2008-03-20 US disclosed
EP-1809657-A1 CYCLIC NONAPEPTIDE AMIDES AiCuris GmbH & Co. KG (DE) 2007-07-25 EP disclosed
WO-2006048156-A1 CYCLIC NONAPEPTIDE AMIDES AICURIS GMBH & CO. KG (DE) 2006-05-11 WO disclosed
US-6685617-B1 4-(((-1-CARBOXY-2-(4-((2,6-DICHLOROBENZOYL)AMINE)PHENYL)ETHYL) AMINO)CARBONYL)-3-OXO-3-THIAZOLIDINEBUTANOIC ACID, USED AS ANTAGONISTS FOR CELLULAR ADHESION MOLECULES, AND ADMINISTERED AS ANTIINFLAMMATORY AGENTS PHARMACIA & UPJOHN COMPANY 2004-02-03 US disclosed
EP-0983275-B1 NOVEL TRIPTOLIDE DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE DISEASES AVENTIS PHARMA INC (US) 2002-08-28 EP disclosed
EP-0983275-A1 NOVEL TRIPTOLIDE DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE DISEASES HOECHST MARION ROUSSEL, INC. (US) 2000-03-08 EP disclosed
US-6004999-A ANTIINFLAMMATORY AGENTS HOECHST MARION ROUSSEL, INC. (US) 1999-12-21 US disclosed
WO-1998052951-A1 NOVEL TRIPTOLIDE DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE DISEASES HOECHST MARION ROUSSEL, INC. (US) 1998-11-26 WO disclosed
EP-0577775-A4 ANTI-THROMBOTIC PEPTIDES AND PSEUDOPEPTIDES. RHONE POULENC RORER INT (US) 1995-01-11 EP disclosed
EP-0577775-A1 ANTI-THROMBOTIC PEPTIDES AND PSEUDOPEPTIDES RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) 1994-01-12 EP disclosed
WO-1992017196-A1 ANTI-THROMBOTIC PEPTIDES AND PSEUDOPEPTIDES RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) 1992-10-15 WO disclosed
US-4985406-A Central nervous system disorders, dopaminergic pathways INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 1991-01-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100204119-A1 4-AMINO-5-OXO-7,8-DIHYDROPYRIMIDO[5,4-F][1,4]OXAZEPIN-6(5H)-YL PHENYL DERIVATIVES DGAT1, DGAT2, MOGAT2 SLC7A5 2310/4885ALPI 1017/4885PKM 2068/4885
US-20100197591-A1 4-AMINO-7,8-DIHYDROPYRIDO[4,3-d]PYRIMIDIN-5(6H)-ONE DERIVATIVES CDK7, DPYD, DHFR SLC7A5 440/4885ALPI 3257/4885PKM 2169/4885
US-20080070884-A1 Antibiotics; novel class of cell wall biosynthesis inhibitors without cross-resistances to known classes of antibiotics; active analogs of lysobactin with a higher ring stability AAAS, PGLS, NRDC SLC7A5 337/4885ALPI 343/4885PKM 1941/4885
US-11661457-B2 IGF-1R antibody-drug-conjugate and its use for the treatment of cancer IGF1R, IGFBP1, IGFBP5 SLC7A5 1491/4885ALPI 2673/4885PKM 4582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.